# Exercise-specific post-translational modification signatures: unveiling precise regulatory mechanisms of molecular exercise language and cellular adaptation

**Authors:** Yinghao Shen, Zhujun Mao, Heming Chen, Wenyue Zhu, Qianhui Guan, Yupeng Yang, Junjie Liu, Li Li

PMC · DOI: 10.3389/fspor.2026.1765170 · Frontiers in Sports and Active Living · 2026-02-13

## TL;DR

This paper explores how different types of exercise create unique protein modification patterns that control cellular adaptation and communication.

## Contribution

Introduces PTM threshold theory and exercise-specific PTM signatures to better understand exercise adaptation.

## Key findings

- Acetylation, ubiquitination, and lactylation are key PTMs in exercise adaptation.
- PTM-centered networks unify exercise regulation and therapeutic strategy development.
- Machine learning with PTM data can enable personalized exercise prescriptions.

## Abstract

Exercise reshapes cellular function and intercellular communication through dynamic post-translational modifications (PTMs) that fine-tune protein activity and inter-organ signaling. However, the traditional aerobic–anaerobic dichotomy does not fully capture PTM-driven regulatory logic across exercise modes. This review centers on the muscle–brain and muscle–liver axes and proposes an operational concept of exercise-specific PTM signatures, emphasizing acetylation, ubiquitination, and lactylation as core PTMs implicated in metabolic memory and adaptive remodeling. To connect exercise intensity with metabolic improvement, we introduce the PTM threshold theory and outline how integrated exercise–PTM–disease target databases, coupled with machine-learning approaches, can support personalized exercise prescription and translation toward exercise pharmacology and rare-disease rehabilitation. Overall, PTM-centered regulatory networks provide a unifying and actionable framework for decoding exercise adaptation and prioritizing therapeutic strategies.

## Full-text entities

- **Genes:** TRAF6 (TNF receptor associated factor 6) [NCBI Gene 7189] {aka MGC:3310, RNF85}, FNDC5 (fibronectin type III domain containing 5) [NCBI Gene 252995] {aka FRCP2, irisin}, NTRK2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 4915] {aka DEE58, EIEE58, GP145-TrkB, OBHD, TRKB, trk-B}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, SLC16A1 (solute carrier family 16 member 1) [NCBI Gene 6566] {aka HHF7, MCT, MCT1, MCT1D}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, IL6R (interleukin 6 receptor) [NCBI Gene 3570] {aka CD126, HIES5, IL-1Ra, IL-6R, IL-6R-1, IL-6RA}, TNFRSF12A (TNF receptor superfamily member 12A) [NCBI Gene 51330] {aka CD266, FN14, TWEAKR}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, KAT2A (lysine acetyltransferase 2A) [NCBI Gene 2648] {aka GCN5, GCN5L2, PCAF-b, hGCN5}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, HCAR1 (hydroxycarboxylic acid receptor 1) [NCBI Gene 27198] {aka FKSG80, GPR104, GPR81, HCA1, LACR1, TA-GPCR}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}
- **Diseases:** fatigue (MESH:D005221), PTM (OMIM:614922), metabolic disorders (MESH:D008659), HIIT (MESH:D000095027), , neurodegenerative, and oncological diseases (MESH:D019636), inflammation (MESH:D007249), muscle hypertrophy (MESH:C536106), Alzheimer's and Parkinson's diseases (MESH:D010300), atherosclerosis (MESH:D050197), hypertension (MESH:D006973), diabetes (MESH:D003920), hypertrophy (MESH:D006984), cancer (MESH:D009369), neuroinflammation (MESH:D000090862), glycogen storage disorders (MESH:D006008), toxicities (MESH:D064420), prediabetes (MESH:D011236)
- **Chemicals:** ATP (MESH:D000255), purine (MESH:C030985), lipid (MESH:D008055), glycogen (MESH:D006003), glucose (MESH:D005947), nitric oxide (MESH:D009569), acetyl (-), oxygen (MESH:D010100), K (MESH:D011188), Lactate (MESH:D019344), fatty acid (MESH:D005227)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12945398/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12945398/full.md

## References

171 references — full list in the complete paper: https://tomesphere.com/paper/PMC12945398/full.md

---
Source: https://tomesphere.com/paper/PMC12945398